p90 Ribosomal S6 kinase (RSK) 4 is a serine-threonine kinase that belongs to the p90RSK family. RSK4 has been proposed as a tumor suppressor gene, related with anti-invasive activity, inhibition of the RAS-mitogen-activated protein kinase (MAPK) pathway and induction of senescence. Despite the related findings, little is known about RSK4 effectors. In human tumors, RSK4 is downregulated even in some benign lesions, such as colon adenomas and breast papillomas, indicating that RSK4 inhibition could be an early event in cellular transformation. For cells to achieve immortality and transformation, it is believed that they must override senescence. In the present study, we found that when RSK4 is inhibited in vitro using short hairpin RNA technology, cells can bypass stress-induced senescence and oncogene-induced senescence: normal human fibroblasts grew following oxidative stress, induction of DNA damage and KRAS V12 or BRAF E600 overexpression. To investigate the RSK4 effectors, we used short hairpin RNA or inhibitor molecules against major senescence mediators. We found that RSK4-induced senescence is mediated through p21, but is independent of p16, p38MAPKs and induction of reactive oxygen species, delimiting RSK4 signaling. These data support the importance of RSK4 for regulating senescence and indicate that downregulation of this kinase could be an important element in facilitating cell transformation.
Introduction
Senescence is a permanent growth arrest activated by normal cells in response to various stress stimuli. Senescence was first described by Hayflick (1) decades ago as a phenomenon that occurred in cultured cells as a consequence of progressive telomere shortening after numerous cell divisions. The phenomenon was called 'replicative senescence'. Subsequently it was observed that other stress stimuli, such as DNA damage, exposure to reactive oxygen species (ROS), and oncogene activation can induce 'premature senescence' in a telomereindependent manner (2) . Several recent reports have demonstrated that oncogene-induced senescence occurs in vivo in human tumors and in mouse models (3) (4) (5) (6) and acts as a protective mechanism against cancer.
Many signals that induce senescence converge on the p19ARF-p53 and p16INK4a-Rb pathways, but utilize different intermediaries. P16 activates the Rb pathway by inhibiting Cyclin D/cyclin-dependent kinase (CDK) 4,6 and p19 activates p53 by inhibiting MDM2; p53 can also be activated by phosphorylation performed by the ataxia telangiectasia mutated (ATM)/ATM and Rad3-related (ATR) (Rad3-related) and/or CHK1/CHK2 proteins. These two pathways can be connected through p21, which is activated by p53; p21, in turn, can activate Rb by inhibiting CycE/Cdk2. Once Rb is activated, it can inactivate the transcription factor E2F. In some senescent cells, E2F target genes are silenced by Rb-dependent chromatin reorganization into discrete foci that are termed senescence-associated-heterochromatin foci (7) . Despite the connection between these two pathways, there are cell type-specific and species-specific differences in the way cells respond when one or the other pathway mediates a senescence response. For example, experimental disruption of telomeres activates only the p53 pathway in mouse cells and both the p53 and the p16-Rb pathways in human cells (8) .
Telomeres consist of repetitive DNA elements at the end of linear chromosomes that protect them from degradation or recombination. Due to the inability of the replication machinery to copy the end of linear molecules, telomeres become shorter at every round of replication. When telomeres are shortened under a minimum threshold, a DNA damage response (9) is activated through ATM, ATR and CHK1-2, which in turn, activate p53, thereby contributing to either apoptosis or replicative senescence (10) . In the case of oncogene-induced senescence, several pathways involving activation of tumor suppressor genes have been described. One model proposes that some oncogenes, such as RAS or STAT5, cause DNA damage (11) , which could occur through ROS generation (12) or through excessive replication due to a sustained oncogenic signal (13, 14) . Consistent with the hypothesis that oncogene activation can produce an accumulation of ROS, ROS also induces senescence via a kinase cascade involving p38 and its effector p38-regulated/activated protein kinase, which can phosphorylate and activate p53 (15) . Although oncogene activation induces a hypermitogenic signal, it has been proposed that the activation is rapidly shut down by a negative feedback signaling network that acts as the true senescence trigger (5). The mechanisms described above are not necessarily exclusive, and depending on the genetic background and tissue type, the proteins connecting oncogene activity to the tumor suppressors p53 and/or pRb might be different. Identification and characterization of new genetic components of the senescence pathways will provide a better understanding of the molecular mechanisms of senescence.
In a previous report, we found that the serine-threonine kinase, p90 ribosomal S6 kinase (RSK) 4, might have an important role regulating senescence and immortalization in colon and renal carcinomas (16) . RSK4 belongs to the p90RSK family, which is composed of six members identified by the presence of two non-identical and active kinase domains (17) . This family includes two protein groups: RSK1-4 are activated by extracellular signal-regulated kinase (ERK) 1 and 2, and are more closely related to each other than the mitogen-stress activated kinases 1 and 2, the other two members of this family.
RSK1-3 are the central mediators of the ERK-mitogen-activated protein kinase (MAPK) pathway in the regulation of cell division, survival and differentiation via phosphorylation of numerous intracellular proteins including transcription factors and coregulators, such as CREB, CBP, p300, c-Fos, IjBa and ERa. Nevertheless, RSK4, the last member of this kinase family identified, has important features that clearly distinguish it from other RSK proteins, involving an inhibitory function in cell proliferation. Depletion of RSK4 seems to suppress p53-dependent cell cycle arrest and reduces messenger RNA expression of the cyclin-dependent inhibitor p21. Myers et al. (18) identified RSK4 as an inhibitor of the RAS-MAPK pathway because of its ability to disrupt mesoderm formation. Another study describes anti-invasive and anti-metastatic activities of RSK4 in breast cancer cell lines both in vitro and in vivo (19) . In our previous study, we observed that RSK4 was downregulated in colon and renal human carcinomas, as well as in early stages of tumorigenesis, for example in colon adenomas. When RSK4 was overexpressed, senescence was induced, and its depletion increased the lifespan of human diploid fibroblasts. Endogenous RSK4 was also increased when senescence was induced. We found that RSK4-mediated senescence was dependent on Rb but not on p53. In the present study, we report that RSK4 inhibition overrides premature senescence in response to oxidative stress, DNA damage and oncogene activation. We also show that RSK4 mediates senescence through p21 activation.
Material and methods
Cell culture and reagents The TIG3 and TIG3 p16-null human diploid fibroblasts immortalized with human telomerase reverse transcriptase (hTERT) used in this study were kindly donated by Dr D.Peeper (The Netherlands Cancer Institute, Amsterdam). Cells were grown in Dulbecco's modified Eagle's medium (Cambrex, Barcelona, Spain) supplemented with 10% fetal calf serum (Labclinic, Barcelona, Spain) and antibiotics (Cambrex). The p38 MAPK inhibitor SB203580 was obtained from Calbiochem (Darmstadt, Germany). N-acetyl-L-cysteine (NAC) and hydrogen peroxide (H 2 O 2 ) were purchased from Sigma (Taufkirchen, Germany). Cisplatin and hydrogen peroxide (H 2 O 2 ) resistance curves For Cisplatin (CDDP) and H 2 O 2 resistance curves, cells were seeded at low density and treated for 2 h with 200 lM of H 2 O 2 or for 6 h with 2 lg/ml of CDDP. After treatment, fresh medium was added and cells were maintained in culture for 3, 6 or 9 days. At these times, cells were washed with phosphatebuffered saline, fixed in 10% formalin and rinsed with distilled water. Cells were stained with 0.1% crystal violet (Sigma) for 30 min, rinsed thoroughly and dried. Cell-associated dye was extracted with 2 ml 10% acetic acid and the relative cell number was determined reading the optical density at 590 nm. A value of 100% was assigned to cells stained just before the treatment. All points within each experiment were determined in duplicate and each experiment was done at least twice with similar results.
Growth curves
Two days after selection, cells were counted and seeded in duplicate every 4 days. Population doublings (PDs) were determined by the following formula: PD 5 Log (Nf/Ni)/Log2, where Nf is the number of cells counted and Ni is the number of cells seeded. Cumulative PD numbers represent the sum of PDs from previous passages. Each curve was done at least twice with similar results, and each time point was determined in duplicate.
Vectors and plasmid construction
The pWZL-RSK4 blasticidin vector was constructed by cloning the respective complementary DNA fragment of RSK4 from pLPCX-RSK4 into the retroviral vector pWZL. The retroviral short hairpin RNA (shRNA) vectors pRetroSuper (pRS)-shp21 and pRS, as well as the pBabe-KRAS V12 vector and pWZL vector were kindly donated by Dr A.Carnero (Centro Nacional de Investigaciones Oncológicas, CNIO, Spain). pMSCVblast-BRAF E600 and pMSCVblast empty vector were kindly donated by Dr D.Peeper. These vectors contain a resistance gene against blasticidin. The retroviral vectors, pLPCX-RSK4 and pLPCXgreen fluorescence protein, and the lentiviral vectors, pLKO.1-shNonTarget (pLKO.1-shNT) and pLKO.1-shRSK4, were generated as described previously (16) .
Lentivirus-based shRNA transduction Lentivirus-based transduction was carried out using a packaging cell line, HEK293T, by cotransfection of pCMV-dR8.91 dvpr (kindly donated by D.Trono, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland) and VSV-G (Clontech, Saint-Germain-en Laye, France). After two consecutive virus infections, cells were selected with the indicated antibiotic.
Retrovirus-based gene transduction
Retrovirus-based gene transduction was carried out using a packaging cell line (GP-293; Clontech) according to the manufacturer's instructions. After two consecutive virus infections, cells were selected with the indicated antibiotic.
Western blot Subconfluent cells were lysed in a lysis buffer (50 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid pH 7.5; 150 mM NaCl; 1% Triton X; 1 mM ethylenediaminetetraacetic acid and 10% glycerol) in the presence of protease and phosphatase inhibitors for 30 min at 4°C. After the lysates were cleared by centrifugation, protein concentrations were determined using the Bradford assay (Bio-Rad Protein Assay, Munich, Germany). About 25-50 lg of protein was denatured and resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad). The primary antibodies used were anti-RSK4 (sc-17178, diluted 1:100; Santa Cruz Biotechnology, Santa Cruz, CA), anti-b-actin (CP01, diluted 1:7000; Calbiochem), anti-p21 WAF1 (MS-891, diluted 1:500; Neomarkers, Fremont, CA), anti-p16 (DB018, diluted 1:200; Deltabiolabs, Gilroy, CA), anti-KRAS (sc-30, diluted 1:200; Santa Cruz Biotechnology) and anti-BRAF (sc-5284, diluted 1:500; Santa Cruz Biotechnology). The secondary antibodies used were donkey anti-goat IgG-horseradish peroxidase (sc-2020, diluted 1:5000; Santa Cruz Biotechnology), sheep anti-mouse IgG-horseradish peroxidase (NA9310, diluted 1:3000; Amersham Pharma-Biotech, Dreieich, Germany) and donkey anti-rabbit IgG-horseradish peroxidase (NA9340, diluted 1:2000; Amersham Pharma-Biotech). Bound antibodies were visualized with an enhanced chemiluminescence detection kit (Amersham Pharma-Biotech). For the p21 band intensities, proteins were quantified by densitometry with the Image J software (version 1.42q, National Institutes of Health, Bethesda, MD), normalized to the intensity of b-actin in each sample and expressed in arbitrary densitometric units.
Analysis of senescence
Senescence-associated b-galactosidase (SA-b-gal) activity was determined with the senescence b-galactosidase kit (Cell Signaling, Beverly, MA), following the manufacturer's instructions. To quantify SA-b-gal activity, at least 500 cells were counted in five random fields using a standard light microscopy.
Colony formation assay
Cells were plated at 7.5 Â 10 4 cells per well in six-well dishes or at 1.7 Â 10 5 in 60 mm plates and cultured for 14 days prior to fixation with 4% paraformaldehyde (Sigma-Aldrich, Taufkirchen, Germany). After fixation, cells were washed with phosphate-buffered saline and stained with 0.1% crystal violet (Sigma) for 30 min, rinsed thoroughly and dried. Each cell type was plated in duplicate for each experiment.
RNA extraction and quantitative reverse transcription-polymerase chain reaction Total RNA was isolated from cells with the RNeasy Mini Kit (Qiagen, Germantown, MD) following the manufacturer's instructions. Random primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA) were used to carry out complementary DNA synthesis from 1.5 lg of total RNA. RSK4 expression was detected using the Taqman Gene Expression Assay (Hs00179523_m1; Applied Biosystems, Carlsbad, CA). The endogenous control PPIA (4326316E; Applied Biosystems) was used as the reference gen. An ABI PRISM 7000 instrument (Applied Biosystems) was used to perform the relative quantification analysis, and data were analyzed with the 7000 Sequence Detection Software, v.1.2.3 (Applied Biosystems). The polymerase chain reaction cycling program consisted of denaturing at 95°C for 10 min and 40 cycles at 95°C for 15 s and annealing and elongation at 60°C for 1 min. The reactions were done in triplicate.
Results

RSK4-induced senescence in TIG3 and TIG3 p16-null human diploid fibroblasts
It is known that human diploid fibroblasts in culture accumulate proteins related with senescence, such as p16 and p21, when they reach the limit of their finite lifespan (20) . In a previous study, we reported that RSK4 overexpression induced a senescence-like phenotype in the IMR90 human diploid fibroblast line (16) . In order to separate the RSK4-induced senescence from lifespan-based events and to clarify the relationship between RSK4 and senescence, we decided to work with the hTERT-expressing fibroblasts, TIG3 and TIG3 p16 null. hTERT expression enables human diploid fibroblasts to bypass replicative senescence without affecting premature senescence (4, 20, 21) .
The RSK4 gene was transduced into these cell lines via retroviral infection. Six days postselection, we observed dramatic morphologic changes characteristic of senescence (2) together with an increment in SA-b-gal activity ( Figure 1A ). This phenotype was independent of p16, as it was also observed in TIG3 p16-null cells. As was described previously (16) , RSK4 induced an increase in p21 expression in both cell lines ( Figure 1B ).
RSK4 inhibition conferred resistance to stress-induced senescence
In a previous study, we found that RSK4 inhibition delays replicative senescence in IMR90 cells (16) . To determine whether RSK4 could also confer resistance to stress-induced senescence, we infected TIG3
Stress-induced and oncogene-induced senescence cells with the lentiviral vector pLKO.1 encoding shRNA against RSK4 (shRSK4) and against a non-target sequence (shNT). Following cell selection, we checked RSK4 inhibition by quantitative real time reverse transcription-polymerase chain reaction (supplementary Figure 1 is available at Carcinogenesis Online). Because subcytotoxic treatments are able to induce senescence (22) , selected cells were seeded at low density and treated with 200 lM of H 2 O 2 for 2 h or 2 lg/ml of CDDP for 6 h. Subsequently, cells were incubated with fresh medium and the relative cell number was measured every 3 days. After either treatment, control cells stopped cell proliferation (its relative cell number did not increase during 9 days) (Figure 2A ) and 73% of cells after H 2 O 2 treatment or 68% of cells after CDDP treatment were positive for the senescence marker SA-b-gal ( Figure 2B) . Nevertheless, cells with RSK4 inhibition resumed proliferation after either treatment and the number of positive cells for SA-b-gal was reduced to 30% after H 2 O 2 treatment or 15% after CDDP treatment (Figure 2A and B) , indicating that cells lacking RSK4 are more resistant to stress-induced senescence.
RSK4 inhibition conferred resistance to oncogene-induced senescence Many genes trigger oncogene-induced senescence, and several reports have now demonstrated that mutations in K-RAS, B-RAF, PTEN and NF1 can trigger cell senescence in vivo (3-6,23-25). Once, we had observed that RSK4 inhibition could reduce stress-induced senescence, we investigated whether RSK4 inhibition could also override oncogene-induced senescence. We infected TIG3 and TIG3 p16-null cell lines with lentiviral vector pLKO.1 encoding shRNA against RSK4 (shRSK4) or against a non-target sequence (shNT). After selection, cells were reinfected with a retroviral vector coding for KRAS V12 or a control. Six days postselection, we analyzed SA-b-gal activity in Fig. 1 . RSK4 induces senescence in TIG3 and TIG3 p16-null human diploid fibroblasts. (A) TIG3 and TIG3 p16-null cells were infected with retrovirus encoding green fluorescence protein or RSK4. After selection, cells were seeded at the same density, and cell morphology and SA-b -gal activity were analyzed 6 days later. Images are all at the same magnification (Â20). (B) Four days after selection, whole cell lysate from each cell line was assessed by immunoblotting for levels of RSK4, p21 and p16. Equal loading was verified by b-actin. cells that had been infected with pLKO.1-shNT vector. In our cell models, KRAS V12 only induced senescence in TIG3, and not in cells lacking p16 (TIG3 p16-null) (supplementary Figure 2 is available at Carcinogenesis Online). This effect has been described previously in other fibroblasts, like Leiden or Q34 fibroblast (26, 27) .
The growth curve analysis on the TIG3 cell line showed that KRAS V12 -induced senescence was bypassed when RSK4 was inhibited ( Figure 3A) . Fourteen days after selection, KRAS, p16 and p21 expression was analyzed by western blot ( Figure 3B ). We observed that KRAS induced an increment of p21 expression that was not produced in cells with RSK4 inhibition, which were still proliferating in spite of KRAS V12 overexpression. This observation suggests that KRAS V12 -induced senescence was bypassed in cells with RSK4 inhibition and that this fact could be due to the lack of p21 expression when RSK4 is inhibited.
BRAF is a downstream RAS effector that is also commonly mutated in human tumors. To test whether RSK4 inhibition could also override BRAF-induced senescence, we overexpressed BRAF E600 in TIG3 and TIG3 p16-null cells that had been previously infected and selected with lentiviral vectors coding for shNT and shRSK4. First, RSK4 expression was measured by reverse transcription-polymerase chain reaction in these cells (supplementary Figure 3 is available at 
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Carcinogenesis Online). Although BRAF is an effector of RAS, BRAF E600 can induce senescence in p16-null cells (4) . Two days after BRAF E600 selection, we seeded cells at low density and performed growth curves. RSK4 inhibition partially rescued BRAF E600 -induced senescence in both TIG3 and TIG3 p16-null ( Figure 4A ). BRAF, p16 and p21 expression were analyzed by western blot ( Figure 4B ). We observed that p16 was induced by BRAF independently of RSK4, nevertheless, we did not observe a clear increment of p21 expression induced by BRAF. These observations indicate that BRAF E600 -induced senescence was bypassed in cells with RSK4 inhibition despite p16 increase.2 RSK4-induced senescence is independent of p38MAPK Some oncogenes induce senescence by a buildup of DNA damage caused by oncogene-driven accumulation of ROS. ROS can trigger senescence via a kinase cascade involving p38MAPK, and it has been described that oncogenic RAS-induced senescence in normal fibroblasts is mediated by activation of the RAF/MEK/ERK and p38 MAPK pathways (15) . To test whether RSK4-induced senescence is due to an accumulation of ROS or is mediated by p38MAPK, we overexpressed RSK4 in TIG3. At day 0 postselection, we seeded cells at low density and treated them with a control solvent (dimethyl sulfoxide), with the p38 MAPK inhibitor SB203580, or with the ROS scavenger N-acetyl-L-cysteine (NAC). After 14 days, colony formation assays showed that neither SB203580 nor NAC were able to inhibit RSK4-induced senescence ( Figure 5A ). RSK4 and p21 expression were analyzed by western blot ( Figure 5B ).
p21 inhibition overrided RSK4-induced senescence Several reports have shown that RSK4 overexpression induces p21 expression and that RSK4 inhibition prevents p21 accumulation (16, 19, 28) . In our previous study, we found that RSK4-induced senescence is dependent on Rb expression (16) . Rb is mainly activated by p16. Nevertheless, RSK4-induced senescence even in TIG3 p16-null cells (Figure 1 ). P21 is a CDK inhibitor that can also activate Rb; hence, to determine whether RSK4-induced senescence is mediated by p21, we infected TIG3 and TIG3 p16-null cells with a retroviral vector coding for shRNA against p21 or an empty vector. Once cells were infected and selected, we reinfected them with a control vector or a vector coding for RSK4. Two days after selection, we seeded cells at low density, and 14 days later, we analyzed colony formation ( Figure  6A ) and RSK4 and p21 expression by western blot ( Figure 6B ). In both cell types, p21 inhibition partially prevented RSK4-induced senescence. Moreover, p21 band intensities were quantified by densitometry and normalized to the intensity of b-actin in each sample ( Figure 6C ).
Discussion
The last member of the p90RSK family discovered was RSK4 (29) . Since its discovery, RSK4 has been described as a component of the p53 pathway (28) and an inhibitor of the RAS-MAPK pathway (18) .
Two recent reports have highlighted the importance of RSK4 in tumorigenesis, with descriptions of its contribution to regulating cell senescence and invasion (16, 19) .
RSK4 is an unusual RSK in that it has very low expression levels and appears to be fully phosphorylated and activated in unstimulated cells (30) . In humans, RSK4 is downregulated in some tumors, such as colon and renal carcinomas, as well as is some benign lesions, such as colon adenomas and benign breast papillomas (16, 31) . RSK4 overexpression has been related to senescence in human fibroblasts and in colon carcinoma cells with CDKN2A mutation and no p53 expression (16) . The aim of this study was to elucidate the role of RSK4 in regulating senescence by analysing the effect of its inhibition in vitro. To achieve this objective, we used a human diploid fibroblast cell line, TIG3, immortalized with the catalytic subunit of telomerase (hTERT). hTERT lengthens the life of fibroblasts without affecting the signals that activate senescence in response to non-telomeric stress stimuli (4, 20, 21) . As was previously seen in normal IMR90 human fibroblasts, we found that RSK4 also induced senescence in our fibroblast model. As was expected, RSK4 overexpression induced SA-b-gal activity, stopped proliferation and increased p21 expression. This phenotype was also observed in TIG3 p16-null cells, supporting the concept that RSK4-induced senescence is p53 (16) and p16 independent.
In the last years, mouse models have yielded evidence that cell senescence has a tumor suppressor role. Genetic deletion of senescence regulatory genes, such as Cdkn2a and Tp53, is related with progression to malignant stages (6, 25, 32) . To investigate whether RSK4 inhibition could also be related with malignancy, we generated two cell models without RSK4 expression using shRNA technology. It is known that a wide variety of anticancer agents induce senescencelike morphological changes and SA-b-gal expression even in tumor cells (22) . H 2 O 2 and CDDP subcytotoxic treatment can induce senescence by accumulation of ROS and induction of DNA damage, respectively (22) . To test whether RSK4 is an important factor mediating this response, we treated cells-expressing shRNA against RSK4 with H 2 O 2 and CDDP and observed that RSK4 inhibition conferred resistance to both stress-induced senescence treatments. This finding indicates that tumors with low RSK4 expression may be more resistant to anticancer drugs, although further investigation is needed to confirm this hypothesis.
Once, we saw that RSK4 inhibition conferred a proliferative advantage, delaying senescence induction, we wondered whether if it could also confer resistance to oncogene-induced senescence. Since its first description over a decade ago, several reports have now demonstrated that oncogene-induced senescence functions to suppress tumor development by preventing progression of benign lesions in the absence of additional co-operating mutations (33, 34) . The finding that RSK4 inhibition also conferred resistance to KRAS V12 and BRAF E600 -induced senescence, indicates that this little known gene may also play an important role in oncogene-induced senescence. This observation, together with clinical data, which has shown that RSK4 is downregulated in premalignant lesions, could indicate that RSK4 inhibition is a prerequisite that allows cells to proliferate after oncogenic alterations occur, such as KRAS and BRAF mutations.
Despite the advances in our understanding of senescence, there is no unified model that integrates all the current findings. DNA damage, replicative stress, ROS, heterochromatin formation and negative feedback signaling have been proposed as factors that promote senescence in response to oncogene mutations (33) . RAS-induced senescence can be activated by an accumulation of ROS and through the p38 MAPK pathway (33) . Treatment with antioxidant agents or the p38 MAPK inhibitor SB203580 can prevent RAS-induced senescence (12, 35) . Since RSK4 inhibition also prevents RAS-induced senescence, we wondered whether RSK4-induced senescence is mediated by ROS generation and the p38 MAPK pathway. To test this hypothesis, we overexpressed RSK4 in the presence of the ROS scavenger NAC or the p38 MAPK inhibitor SB203580 and saw no effect, indicating that RSK4-induced senescence was independent of ROS induction and the p38 MAPK pathway.
Although several mechanisms can regulate senescence, in all cases, the signals function through Rb and p53, using different intermediates. RSK4 was first described as a mediator of p53-dependent cell cycle arrest (28) . However, RSK4 can induce senescence even in the absence of p53, and RSK4 expression increases even in p53-null cell lines after different stress stimuli, indicating that RSK4 can also function in a p53-independent way (16) . Previous findings indicated that RSK4 regulates senescence mainly through the classical p16/Rb pathway (16), but p16 inhibition did not prevent RSK4 senescence induction in this study, which suggests that RSK4 does not regulate Rb through this pathway. It has been proposed that RSK4 could regulate p21 expression, even at the messenger RNA level, although it is not known if RSK4 regulates p21 at the transcriptional level or if it stabilizes p21 messenger RNA (28) . In this study, we found that RSK4-induced senescence is dependent on p21 expression, since inhibition of p21 allowed proliferation in cells with RSK4 overexpression. Since p21 is a major CDK inhibitor that can also activate Rb, we propose that RSK4 takes part in senescence by regulating p21 in a p53-independent manner, and that p21 induces senescence through Rb hypophosphorylation. The existence of signaling pathways that activate senescence independently of p53 and p16 would be a double barrier to cellular transformation. In our cell model of KRAS V12 -induced senescence, we observed that p21 was not overexpressed in response to KRAS V12 in cells lacking RSK4, indicating that p21 expression could be dependent of RSK4. Nevertheless, p21 inhibition did not suffice to completely prevent the RSK4-induced phenotype in TIG3. Moreover, p21 is not considered a major regulator of oncogeneinduced senescence, and although it is overexpressed in human fibroblasts in response to RAS (2, 36, 37) , p21 inhibition does not prevent H-RAS-induced senescence (37) . In the case of BRAF, p21 is not upregulated after BRAF overexpression in different cell models (4, 38, 39) . Since RSK4 inhibition sufficed to partly prevent BRAF E600 -induced senescence, it is possible that RSK4 could regulate factors other than p21 that participate in senescence. BRAF overexpression upregulates IGFBP7 synthesis and secretion, which regulates senescence in a feedback-negative way, inhibiting the BRAF/MEK/ERK pathway (40) . A similar negative feedback mechanism has been proposed to occur in RAS-induced neurofibromas (5) . In the present study, we investigated the relationship between RSK4 and p21 and observed that p21 is necessary for RSK4-induced senescence, even though RSK4 has been described as an inhibitor of the RAS-MAPK pathway (18) ; thus, this role of RSK4 could also be important for oncogene-induced senescence regulation.
In this study, the effect of RSK4 inhibition in vitro is reported. Although the exact mechanisms behind the action of RSK4 remain unknown, RSK4 seems to be an important regulator of senescence, mainly through p21, and its downregulation may confer a proliferative advantage. Further study of RSK4 is needed; deeper understanding of the RSK4 pathway could allow its manipulation in the design new therapeutic strategies for cancer. Supplementary Figures 1-3 
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